PNC-27 is an experimental peptide made from part of p53, a protein that normally helps stop cells from turning cancerous, joined to a sequence that lets it get inside cells.[4][5] In lab dishes and mice it killed many kinds of cancer cells while largely sparing normal cells.[5][8] But it has never been tested in people: we found no registered or published human trials.[13] In 2017, FDA warned cancer patients not to buy or use it after finding bacteria in a sample.[1][2]
What is PNC-27?
PNC-27 contains amino acids 12 to 26 of p53, the region that binds a protein called HDM-2 (also known as MDM2), linked to penetratin, a cell-entry sequence from a fruit-fly protein.[4][5] A shorter version is called PNC-28.[7]
Most of the research comes from one academic group led by Matthew Pincus and Josef Michl in Brooklyn, New York.[5][11] A 2020 leukemia study at City of Hope used peptide supplied by a company, Oncolyze, and one author of a 2024 review was employed by a company called Nomcan.[8][11]
How PNC-27 works (in lab studies)
The group’s lab work suggests this sequence of events:[5][6][11]
- Many cancer cells carry HDM-2 on their outer membranes; the normal cell lines tested carried little or none.
- PNC-27 binds that membrane HDM-2.
- The bound peptide forms pores in the membrane, and the cancer cell bursts (a form of cell death called necrosis, rather than the programmed cell death, or apoptosis, typical of standard chemotherapy).[4]
In another experiment, the team labeled both ends of the peptide with different fluorescent dyes and concluded that it works as the whole, intact peptide rather than as broken-down fragments.[6] When the team added membrane HDM-2 to normal breast cells that PNC-27 usually spared, those cells became vulnerable to it.[5]
What PNC-27 research has found
Cell studies
- Breast cancer cells: the original p53-penetratin peptide killed several breast cancer lines, with minimal harm to normal breast cells.[4]
- Ovarian cancer: PNC-27 killed cells freshly taken from 2 patients’ ovarian tumors, plus chemotherapy-resistant ovarian cancer lines.[9]
- Cervical cancer: in a 2025 study, it killed a cervical cancer cell line but not a normal cervical cell line.[10]
Animal studies
- Pancreatic tumors (PNC-28): in mice with transplanted rat pancreatic cancer cells, two weeks of the peptide given into the abdomen at the same time the tumors were implanted there destroyed them. Given at a distant site, it slowed growth, but tumors started growing again after treatment.[7]
- Leukemia: in mice carrying human or mouse acute myeloid leukemia, PNC-27 killed leukemia cells, including leukemia stem cells, while sparing normal blood-forming stem cells.[8]
Has PNC-27 been tested in humans?
No. ClinicalTrials.gov lists no studies of PNC-27,[13] and we found no published human trial or case series in PubMed. The developers’ own 2024 review describes results only in cells and mice.[11] That means there is no evidence about whether it shrinks tumors in people, what dose would be needed, or what harm it might cause.
PNC-27 dosage
There is no studied human dose. Any dose sold online or by clinics abroad is a guess, not a number from a trial. We do not provide dosing for an untested cancer product.
PNC-27 side effects and risks
- Unknown human toxicity: no human safety data exist.
- Contamination: FDA’s lab found the bacterium Variovorax paradoxus in a PNC-27 solution meant for inhalation. FDA warned that contaminated products can cause serious, potentially life-threatening infections, especially in young children, older adults, pregnant women and people with weakened immune systems, which includes many people with cancer. FDA said it had not received reports of serious illness linked to the product at the time.[1][3]
- Delayed treatment: the largest risk is using it instead of proven treatment. Choosing alternative medicine alone for non-metastatic breast, prostate, lung or colorectal cancer was linked to 2.5 times the risk of death in a 2018 US study.[12]
FDA warning and legal status
- FDA warning (January 2017): according to news coverage of the announcement (FDA’s original notice is no longer online), FDA told consumers not to buy or use PNC-27 as a cancer treatment, said it had not evaluated the product’s safety or effectiveness, and said it had not approved it for any disease.[1] At the time, it was sold online as an IV solution, an inhaled solution and vaginal and rectal suppositories, and the seller’s website claimed it could treat any form of cancer.[3] FDA described it as an unapproved drug promoted for treating cancer.[2]
- Who sold it: reports at the time said it was offered to doctors and hospitals outside the US.[3]
- Sports: not named on WADA’s 2026 list, but in our reading it falls under the S0 category for unapproved substances, which is banned at all times.[14]
This is general information, not legal advice.
The bottom line
PNC-27 is an interesting lab idea with a plausible mechanism and promising cell and mouse results.[5][8] It is not a proven cancer treatment, and there is no human evidence at all.[13] For context on how we rate early-stage compounds, see our longevity peptides overview and our profiles of epitalon, another peptide studied for cancer effects only in animals, and thymosin alpha-1, an immune peptide that, unlike PNC-27, has at least some human data.
